Express Pharma

USFDA gives tentative approval to Zydus’s Levomilnacipran extended-release capsules

The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad

2 122

The United States Food and Drugs Administration (USFDA) has given tentative approval to Zydus Lifesciences to market Levomilnacipran extended-release capsules, 20 mg, 40 mg, 80 mg and 120 mg, according to a company statement.

Levomilnacipran is a Serotonin and Norepinephrine Reuptake Inhibitor (SNRI) indicated for the treatment of Major Depressive Disorder (MDD) in adults. The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, the statement said.

- Advertisement -

2 Comments
  1. soundos says

    Your blog is very informative. thanks for Sharing this blog.

  2. djamila_st says

    This article is an appealing wealth of informative data that is interesting and well-written. I commend your hard work on this and thank you for this information. You’ve got what it takes to get attention.

Leave A Reply

Your email address will not be published.